Literature DB >> 8622727

Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy.

B Schmidt1, K V Toyka, R Kiefer, J Full, H P Hartung, J Pollard.   

Abstract

Prompted by observations in experimental autoimmune neuritis we reanalyzed immunohistochemically the inflammatory infiltrates in sural nerve biopsies of 22 cases with Guillain-Barre syndrome (GBS) and 13 cases with chronic inflammatory demyelinating polyneuropathy (CIDP). Endoneurial infiltration of CD3+ T cells was found in 20 cases of GBS (median 5.5 cells/mm(2)) and in 10 cases of CIDP (5 cells). Epineurial T cells were present in all GBS cases (19.5 cells) and in 11 CIDP cases (21 cells). CD68+ macrophages were abundant in these neuropathies and often occurred in endoneurial perivascular clusters. In GBS subgroups the number of endoneurial T cells was significantly higher in patients with hypoesthesia and abnormal electrophysiological findings in the sural nerve. In CIDP hypoesthesia was associated with significantly higher numbers of macrophages. Our study also indicates that other factors including the time point of biopsy or previous corticosteroid treatment may influence the inflammatory cell profile. Quantifying cell infiltration may aid in establishing the diagnosis of an immunoneuropathy in patients with mild and noncharacteristic pathology.

Entities:  

Mesh:

Year:  1996        PMID: 8622727     DOI: 10.1002/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  35 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

3.  Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance.

Authors:  C D Schmid; M Stienekemeier; S Oehen; F Bootz; J Zielasek; R Gold; K V Toyka; M Schachner; R Martini
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 4.  Inflammatory neuropathies.

Authors:  Hannah R Briemberg; Anthony A Amato
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

5.  Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Chaoling Dong; Kelsey M Greathouse; Rebecca L Beacham; Steven P Palladino; E Scott Helton; Eroboghene E Ubogu
Journal:  Exp Neurol       Date:  2017-02-16       Impact factor: 5.330

Review 6.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 7.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

8.  IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration.

Authors:  Collin-Jamal Smith; Denise E Allard; Yan Wang; James F Howard; Stephanie A Montgomery; Maureen A Su
Journal:  J Immunol       Date:  2018-01-24       Impact factor: 5.422

9.  Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy.

Authors:  S Kuwabara; K Ogawara; S Misawa; M Mori; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

10.  The pathogenic relevance of αM-integrin in Guillain-Barré syndrome.

Authors:  Chaoling Dong; Steven P Palladino; Eric Scott Helton; Eroboghene E Ubogu
Journal:  Acta Neuropathol       Date:  2016-07-26       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.